Rodent ischemic stroke models and their relevance in preclinical research
Abstract Stroke is a leading cause of death and disability worldwide, with ischemic stroke caused by an occluded vessel accounting for the majority of cases. Current treatments are limited to recanalization, either through thrombectomy or thrombolysis. Approved pharmacological interventions to suppr...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-12-01
|
| Series: | Neuroprotection |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/nep3.62 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849715930302513152 |
|---|---|
| author | Maria Thaysen Emil Westi Andrew N. Clarkson Petrine Wellendorph Mie Kristensen |
| author_facet | Maria Thaysen Emil Westi Andrew N. Clarkson Petrine Wellendorph Mie Kristensen |
| author_sort | Maria Thaysen |
| collection | DOAJ |
| description | Abstract Stroke is a leading cause of death and disability worldwide, with ischemic stroke caused by an occluded vessel accounting for the majority of cases. Current treatments are limited to recanalization, either through thrombectomy or thrombolysis. Approved pharmacological interventions to suppress stroke‐associated excitotoxicity and neuroinflammatory events, leading to brain tissue death, are still lacking. Although numerous preclinical studies have been performed, they have yet to be translated into clinically relevant interventions. First‐line preclinical in vivo studies include the use of rodent ischemic stroke models, which vary in terms of how well they replicate human stroke pathophysiology and phenotype (including the formation of blood clot, blood–brain barrier disruption, neuroinflammation, and edema generation). Thus, rodent ischemic stroke models must be carefully chosen according to the specific pharmacological intervention to be tested. In this review, we aimed to provide an overview of the five most commonly used rodent ischemic stroke models and critically assess their advantages and limitations, with a primary focus on the acute phases of stroke. |
| format | Article |
| id | doaj-art-14e4ab7ffee04d26b0a7e7df9a8d578b |
| institution | DOAJ |
| issn | 2770-7296 2770-730X |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Wiley |
| record_format | Article |
| series | Neuroprotection |
| spelling | doaj-art-14e4ab7ffee04d26b0a7e7df9a8d578b2025-08-20T03:13:11ZengWileyNeuroprotection2770-72962770-730X2024-12-012429630910.1002/nep3.62Rodent ischemic stroke models and their relevance in preclinical researchMaria Thaysen0Emil Westi1Andrew N. Clarkson2Petrine Wellendorph3Mie Kristensen4Department of Pharmacy, Faculty of Health and Medical Sciences University of Copenhagen Copenhagen DenmarkDepartment of Drug Design and Pharmacology, Faculty of Health and Medical Sciences University of Copenhagen Copenhagen DenmarkREGENBIO Consultants Limited Dunedin New ZealandDepartment of Drug Design and Pharmacology, Faculty of Health and Medical Sciences University of Copenhagen Copenhagen DenmarkDepartment of Pharmacy, Faculty of Health and Medical Sciences University of Copenhagen Copenhagen DenmarkAbstract Stroke is a leading cause of death and disability worldwide, with ischemic stroke caused by an occluded vessel accounting for the majority of cases. Current treatments are limited to recanalization, either through thrombectomy or thrombolysis. Approved pharmacological interventions to suppress stroke‐associated excitotoxicity and neuroinflammatory events, leading to brain tissue death, are still lacking. Although numerous preclinical studies have been performed, they have yet to be translated into clinically relevant interventions. First‐line preclinical in vivo studies include the use of rodent ischemic stroke models, which vary in terms of how well they replicate human stroke pathophysiology and phenotype (including the formation of blood clot, blood–brain barrier disruption, neuroinflammation, and edema generation). Thus, rodent ischemic stroke models must be carefully chosen according to the specific pharmacological intervention to be tested. In this review, we aimed to provide an overview of the five most commonly used rodent ischemic stroke models and critically assess their advantages and limitations, with a primary focus on the acute phases of stroke.https://doi.org/10.1002/nep3.62animal modelsendothelin‐1 induced strokeexcitotoxicityischemic strokemiddle cerebral artery occlusionphotothrombotic stroke |
| spellingShingle | Maria Thaysen Emil Westi Andrew N. Clarkson Petrine Wellendorph Mie Kristensen Rodent ischemic stroke models and their relevance in preclinical research Neuroprotection animal models endothelin‐1 induced stroke excitotoxicity ischemic stroke middle cerebral artery occlusion photothrombotic stroke |
| title | Rodent ischemic stroke models and their relevance in preclinical research |
| title_full | Rodent ischemic stroke models and their relevance in preclinical research |
| title_fullStr | Rodent ischemic stroke models and their relevance in preclinical research |
| title_full_unstemmed | Rodent ischemic stroke models and their relevance in preclinical research |
| title_short | Rodent ischemic stroke models and their relevance in preclinical research |
| title_sort | rodent ischemic stroke models and their relevance in preclinical research |
| topic | animal models endothelin‐1 induced stroke excitotoxicity ischemic stroke middle cerebral artery occlusion photothrombotic stroke |
| url | https://doi.org/10.1002/nep3.62 |
| work_keys_str_mv | AT mariathaysen rodentischemicstrokemodelsandtheirrelevanceinpreclinicalresearch AT emilwesti rodentischemicstrokemodelsandtheirrelevanceinpreclinicalresearch AT andrewnclarkson rodentischemicstrokemodelsandtheirrelevanceinpreclinicalresearch AT petrinewellendorph rodentischemicstrokemodelsandtheirrelevanceinpreclinicalresearch AT miekristensen rodentischemicstrokemodelsandtheirrelevanceinpreclinicalresearch |